Product
UGN-201
2 clinical trials
6 indications
Indication
Bladder CancerIndication
NMIBCIndication
Bladder Carcinoma in SituIndication
Bladder Urothelial CarcinomaIndication
Urothelial Carcinoma RecurrentIndication
BladderClinical trial
A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBCStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical CystectomyStatus: , Estimated PCD: 2024-08-31